n- (2,6-bis (1-methylethyl) phenyl) -N '- ((1- (4- (dimethylamino) phenyl) cyclopentyl) methyl) urea hydrochloride solid drug form and related compositions, methods and kits the same
AIMESTHER BETANCOURT,CHARLES UZARAMA,HERMAN CHEN,MARTIN DOUGLAS PHILLIPS,ROBERT MATUNAS,ROCH THIBERT,STEPHEN WARREN HUNT III
申请号：
BR112017006287
公开号：
BR112017006287A2
申请日:
2015.09.25
申请国别(地区):
BR
年份:
2017
代理人:
摘要：
Summary - n- (2,6-bis (1-methylethyl) phenyl) -n '- ((1- (4- (dimethylamino) phenyl) cyclopentyl) methyl) urea hydrochloride solid drug form and compositions, methods and kits related to it? a new form of n- (2,6-bis (1-methylethyl) phenyl) -n '- ((1- (4- (dimethylamino) phenyl) cyclopentyl) methyl) urea hydrochloride solid drug (also referred to as above) -101 ') suitable for oral dosage, and related compositions, methods and kits are described. atr-101 has particular utility in treating, for example, abnormal adrenocortical cellular activity, including adrenocortical carcinoma (acc), congenital adrenal hyperplasia (cah), and cushing syndrome.resumo ?forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia e composições, métodos e kits relacionados à mesma? uma nova forma de fármaco sólida de cloridreto de n-(2,6-bis(1-metiletil)fenil)-n?-((1-(4-(dimetilamino)fenil)ciclopentil)metil)ureia (também referida ?atr-101?) adequada para dosagem oral, e composições, métodos e kits relacionados à mesma são descritos. atr-101 apresenta utilidade particular no tratamento, por exemplo, de atividade celular adrenocortical anormal, incluindo carcinoma adrenocortical (acc), hiperplasia adrenal congênita (cah) e síndrome de cushing.
